Showing 18,481 - 18,500 results of 42,560 for search '(( a point decrease ) OR ( 50 ((((mean decrease) OR (we decrease))) OR (a decrease)) ))', query time: 1.34s Refine Results
  1. 18481

    image1_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.jpeg by Jordi Rodon (201558)

    Published 2021
    “…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”
  2. 18482

    table5_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

    Published 2021
    “…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”
  3. 18483

    table4_Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.pdf by Jordi Rodon (201558)

    Published 2021
    “…Although different antivirals are given for the clinical management of SARS-CoV-2 infection, their efficacy is still under evaluation. Here, we have screened existing drugs approved for human use in a variety of diseases, to compare how they counteract SARS-CoV-2-induced cytopathic effect and viral replication in vitro. …”
  4. 18484
  5. 18485
  6. 18486
  7. 18487
  8. 18488
  9. 18489
  10. 18490

    Table 1_Association of lifestyle factors with mortality risk in people with chronic obstructive pulmonary disease: a prospective cohort study.docx by Yue Zhang (30585)

    Published 2025
    “…During a median follow-up of 5.8 years, compared with patients with low LE8 scores, those with moderate and high score presented decreased all-cause mortality (both log-rank p < 0.05) and increased 10-year survival rates (63.6, 72.4 and 89.9%, respectively). …”
  11. 18491
  12. 18492

    Table_1_Seasonal variation in the detection rate and all-cause in-hospital mortality of AKI in China: A nationwide cohort study.pdf by Jiaqi Li (220961)

    Published 2022
    “…AKI was defined according to the 2012 Kidney Disease Improving Global Outcomes AKI creatinine criteria or expanded criteria of increase or decrease in serum creatinine level of 50% during the hospital stay. …”
  13. 18493
  14. 18494
  15. 18495
  16. 18496
  17. 18497
  18. 18498
  19. 18499
  20. 18500